May 22, 2018
FDA to review Zynquista(TM) (sotagliflozin) as potential treatment for type 1 diabetes
Apr 27, 2018
Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
Apr 12, 2018
INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Mar 16, 2018
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
Mar 11, 2018
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
Mar 06, 2018
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
Feb 26, 2018
New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
Jan 02, 2018
Lawsuits Filed Against J&J Related to its Drug Invokana
Nov 14, 2017
INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
Nov 03, 2017
INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Oct 02, 2017
Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Sep 13, 2017
New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
Sep 08, 2017
Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin
Sep 05, 2017
Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
Aug 15, 2017
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
Jul 31, 2017
Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes
Jun 21, 2017
New England Journal of Medicine Publishes Results from Aetion Real-World Data Analysis
Jun 12, 2017
Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease
Jun 12, 2017
Major Study Heralds New Era In Treatment Of Type 2 Diabetes
Jun 12, 2017
INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program